Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.

@article{Shi2015ResultsFA,
  title={Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.},
  author={Yuankai Shi and Mei-ling Dong and Xiao-nan Hong and Weijing Zhang and Jifeng Feng and Jun Zhu and Li Yu and Xiao-yan Ke and Zhi Xiang Shen and Yong-Sheng Fan and Weichen Li and Xie lan Zhao and Junyuan Qi and He Huang and Dao Bing Zhou and Zhiqiang Ning and Xian-Ping Lu},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2015},
  volume={26 8},
  pages={1766-71}
}
BACKGROUND Chidamide is a novel benzamide type of subtype-selective histone deacetylase (HDAC) inhibitor with unique mechanisms of action compared with marketed HDAC inhibitors. This phase II study was to evaluate the efficacy and safety of chidamide in relapsed or refractory peripheral T-cell lymphoma (PTCL) in Chinese population. PATIENTS AND METHODS Patients with relapsed or refractory PTCL of different subtypes received chidamide of 30 mg orally twice per week. The primary end point was… CONTINUE READING
47 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 47 extracted citations

Similar Papers

Loading similar papers…